Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00263042 · ClinicalTrials.gov registry record · Phase 3
Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes
A Phase 3 study, sponsored by Sanofi.
- Terminated
- Registry status
- Phase 3
- Development phase
- 18,695
- Enrollment target
NCT00263042: Clinical Trial Phase 3 study, sponsored by Sanofi.
NCT00263042 is a Phase 3 study that was terminated before completion, run by Sanofi. The registered enrollment target is 18,695 participants, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2325% higher). According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00263042, a Phase 3 study, was terminated before completion, sponsored by Sanofi.
- TERMINATED
- Registry status
- Phase 3
- Development phase
- 18,695 participants
- Enrollment target
Study Summary
The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors. The secondary objective is to show whether rimonabant reduces the risk of MI, stroke, CV death, or CV hospitalization in these patients.
Interventions
- DRUG Rimonabant
- DRUG Placebo (for Rimonabant)
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 18,695 participants |
| Start Date | 2005-12 |
| Est. Completion | 2009-04 |
| Phase | Phase 3 |
Why NCT00263042 stopped before completion
NCT00263042 is an interventional study that assigns participants to a tested intervention. Its 18,695 participants enrollment target places it among the larger protocols in the corpus, above the 771-participant average among 15,282 other Phase 3 trials with a reported enrollment target (2325% higher).
The record links to 0 conditions, and to 2 interventions - of which Rimonabant is the first listed.
NCT00263042 does not publish any study locations in the registry export this page uses.
Frequently Asked Questions
What is clinical trial NCT00263042 about?
NCT00263042 is a clinical study titled "Comprehensive Rimonabant Evaluation Study of Cardiovascular ENDpoints and Outcomes". The primary objective is to show whether rimonabant reduces the risk of a heart attack (MI), stroke, or death from an MI or stroke in patients with abdominal obesity with other cardiovascular (CV) risk factors. The secondary objective is to show whether rimonabant reduces the risk of MI, stroke, CV...
What is the current status of trial NCT00263042?
This trial is currently terminated. It is a Phase 3 study. The enrollment target is 18,695 participants. The study started on 2005-12. Estimated completion is 2009-04.
What interventions are being tested in trial NCT00263042?
The interventions under investigation include: Rimonabant (DRUG), Placebo (for Rimonabant) (DRUG).
Who is sponsoring clinical trial NCT00263042?
This trial is sponsored by Sanofi, which has 713 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
How this trial's enrollment target compares
Where NCT00263042's enrollment target sits among peer trials
18,695 11th of 2000 higher than 1,990 of 2,000 other Phase 3 trials
participants (enrollment target), bucketed by value
Each bar is a band; taller bars hold more other Phase 3 trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.
Source ClinicalTrials.gov registry export · 2026-08-08
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT04372875 · 18,500 participants · NA
Health Information Technology to Reduce Disparities in Adolescent Health Outcomes: A Pragmatic Trial
- NCT05555095 · 19,331 participants
Examining Digital Health Care Delivery Models Through Medicaid Collaborative
- NCT04110522 · 18,000 participants · NA
Psoriatic Arthritis D2P Screening
- NCT05513833 · 18,000 participants · NA
School Screening and Telemedicine Specialty Referral to Address Childhood Hearing Loss in Rural Kentucky
Similar registry start date
- NCT05988463 · started 2027-01-01 · Phase 1
Dose-Escalation Study of Artesunate Patients With IPF
- NCT07219706 · started 2026-12-10 · NA
Dietary Fiber and Time Restricted Eating
- NCT02831335 · started 2026-12-01
Technical Development of Multi-Parametric Renocerebral MRI
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia